ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

LENZ LENZ Therapeutics Inc

18.54
-0.09 (-0.48%)
Jun 14 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 127,008
Bid Price 18.00
Ask Price 19.00
News -
Day High 19.48

Low
14.42

52 Week Range

High
24.59

Day Low 17.89
Company Name Stock Ticker Symbol Market Type
LENZ Therapeutics Inc LENZ NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.09 -0.48% 18.54 17:30:00
Open Price Low Price High Price Close Price Prev Close
17.89 17.89 19.48 18.54 18.63
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,047 127,008 $ 18.51 $ 2,351,537 - 14.42 - 24.59
Last Trade Time Type Quantity Stock Price Currency
17:31:14 71 $ 18.00 USD

LENZ Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
474.17M 25.53M - 0 -124.65M -4.88 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

LENZ Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No LENZ Message Board. Create One! See More Posts on LENZ Message Board See More Message Board Posts

Historical LENZ Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week15.0419.9814.920118.20180,8063.5023.27%
1 Month16.5019.9814.4216.63180,9372.0412.36%
3 Months15.9824.5914.4217.23159,9032.5616.02%
6 Months15.9824.5914.4217.23159,9032.5616.02%
1 Year15.9824.5914.4217.23159,9032.5616.02%
3 Years15.9824.5914.4217.23159,9032.5616.02%
5 Years15.9824.5914.4217.23159,9032.5616.02%

LENZ Therapeutics Description

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.

Your Recent History

Delayed Upgrade Clock